Logo

Transplant Genomics: John Holman

Jan 10, 2020

Mansfield, Massachusetts-based Transplant Genomics has appointed John Holman as VP of Medical Affairs. He will replace Roy First, who will continue working as senior clinical advisor. Prior to TGI, Holman served as VP of Immunology and Translational Medicine at Quark Pharmaceuticals. He has also served as VP of clinical research at Myriad Genetics for three years. Prior to Myriad, Holman served as executive medical director as Astellas. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.